Charles Schwab’s BioAge Labs BIOA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.25M Buy
317,258
+43,887
+16% +$608K ﹤0.01% 2749
2026
Q2
$6.7M Buy
273,371
+26,095
+11% +$471K ﹤0.01% 2337
2026
Q1
$4.32M Buy
247,276
+27,434
+12% +$528K ﹤0.01% 2463
2025
Q4
$2.91M Buy
219,842
+28,459
+15% +$252K ﹤0.01% 2642
2025
Q3
$1.13M Buy
191,383
+71,071
+59% +$333K ﹤0.01% 2910
2025
Q2
$497K Buy
120,312
+30,335
+34% +$122K ﹤0.01% 3138
2025
Q1
$338K Buy
89,977
+5,110
+6% +$23.6K ﹤0.01% 3177
2024
Q4
$491K Buy
+84,867
New +$1.46M ﹤0.01% 3143

Other funds holding BIOA

Charles Schwab's BIOA Position: Q3 2026 in Review

Charles Schwab increased its BioAge Labs (BIOA) stake by 16% in Q3 2026, buying an estimated $608K and bringing the position to 317,258 shares worth $2.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2749.

Charles Schwab first reported a position in BIOA in Q4 2024 and has held it in 8 quarters since. The position peaked at $6.7M in Q2 2026. 162 funds tracked by Wall St. Rank hold BIOA as of Q3 2026.

  • Charles Schwab held 317,258 shares of BioAge Labs worth $2.25M as of Q3 2026.
  • Charles Schwab bought 43,887 BioAge Labs shares in Q3 2026, an estimated $608K.
  • BioAge Labs made up ﹤0.01% of Charles Schwab's portfolio in Q3 2026, its #2749 holding.
  • Charles Schwab first reported a position in BioAge Labs in Q4 2024 and has held it in 8 quarters since.
  • Charles Schwab's BioAge Labs position peaked at $6.7M in Q2 2026.
  • 162 funds tracked by Wall St. Rank held BioAge Labs as of Q3 2026.

Based on Charles Schwab's 13F filing for Q3 2026, filed 16 Nov 2026.